Studies on metastatic ovarian cancer have shown (19) that inhibiting TKT expression blocks the proliferation of the SKOV-3 cell line, which is an ovarian cancer cell line, and that oxythiamine, an inhibitor of TKT activity, significantly inhibits the proliferation of four ovarian cancer cell lines and primary serous ovarian cancer cells isolated from the patient’s ascites. Here, TKT is linked to ovarian serous adenocarcinoma.